FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2042-2044 November 9, 2006 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Imagine you had a database of the gene-expression signatures of human diseases and their responses to therapeutic drugs. Its use could result in an unprecedented understanding of the interconnectivity of disease pathways and might also lead to the rational design of an optimal treatment or uncover new strategies for treating disease. Such a crystal ball does not yet exist, but a report by Lamb et al.¹ offers a glimpse of this vision in a laboratory setting.

The traditional approach to developing new therapeutic drugs involves the painstaking identification of an individual drug target, such as a receptor or ion channel, . . . [Full Text of this Article]

Source Information

From RxGen, New Haven, CT.

This article has been cited by other articles:

• Li, L., Fridley, B., Kalari, K., Jenkins, G., Batzler, A., Safgren, S., Hildebrandt, M., Ames, M., Schaid, D., Wang, L. (2008). Gemcitabine and Cytosine Arabinoside Cytotoxicity: Association with Lymphoblastoid Cell Expression. Cancer Res. 68: 7050-7058 [Abstract] [Full Text]  
• Ioannidis, J. P A (2007). Genetic and molecular epidemiology. J. Epidemiol. Community Health 61: 757-758 [Abstract] [Full Text]